IN THE SPOTLIGHT

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Clinical and structural insights into concurrent EGFR and MET exon 14 skipping mutations in NSCLC: a multi-center series

Clinical and structural insights into concurrent EGFR and MET exon 14 skipping mutations in NSCLC: a multi-center series

Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study

Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study

Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC

Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC

李醒亚教授:DESTINY-Lung05 研究再添获益新证,德曲妥珠单抗有望引领 HER2 变异 NSCLC 治疗迈向新纪元_腾讯新闻

李醒亚教授:DESTINY-Lung05 研究再添获益新证,德曲妥珠单抗有望引领 HER2 变异 NSCLC 治疗迈向新纪元_腾讯新闻

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC

Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC

Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC